Theravance Biopharma
OverviewSuggest Edit
Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. It focuses on several therapeutic areas, including infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease.
| Type | Public | |
| Founded | 1996 | |
| HQ | Dublin, IE | Map |
| Website | theravance.com | |
| Culture score | B- | More |
Recent NewsAll News
- Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares
- Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
- Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
- Theravance Biopharma and Mylan Expand YUPELRI (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
Key People/Management at Theravance Biopharma
Rick Winningham
Director, CEO
Eran Broshy
Director
Dennis O. Driver
Senior Vice President, Human Resources, Organizational and Leadership Development
Gary Barrera
Director
Robert V. Gunderson
Director
Rhonda F. Farnum
Vice President, Sales & Marketing
Theravance Biopharma Office Locations
Theravance Biopharma has offices in Dublin and San Francisco
Dublin, IE (HQ)
Connaught House, 1 Burlington Rd
San Francisco, US
901 Gateway Boulevard
Theravance Biopharma Financials and Metrics
Theravance Biopharma Revenue
Theravance Biopharma's revenue was reported to be $60.37 m in FY, 2018 which is a 292.4% increase from the previous period.
| USD | |
|---|---|
Revenue (FY, 2018) | 60.4m |
Revenue growth (FY, 2017 - FY, 2018), % | 292.4% |
Gross profit (FY, 2018) | 59.7m |
Gross profit margin (FY, 2018), % | 98.8% |
Net income (FY, 2018) | (215.5m) |
EBIT (FY, 2018) | (238.8m) |
Market capitalization (27-Mar-2020) | 1.3b |
Closing stock price (27-Mar-2020) | 21.1 |
Cash (31-Dec-2018) | 378.0m |
EV | 1.2b |
Theravance Biopharma's current market capitalization is $1.3 b.
Annual
Annual
| USD | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
Cash | 344.7m | 89.0m | 378.0m |
Accounts Receivable | 646.0k | 2.3m | 620.0k |
Inventories | 12.2m | 16.8m | |
Current Assets | 528.5m | 378.7m | 532.8m |
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 128.8m | 148.4m | 86.6m | 169.9m | 139.6m | 91.3m | 125.8m | 103.9m | 101.2m |
Accounts Receivable | 1.5m | 1.9m | 873.0k | 1.2m | 1.3m | 1.6m | 2.0m | 3.4m | 3.0m |
Inventories | 9.4m | 9.8m | 12.5m | 13.2m | 12.1m | 15.3m | 17.2m | 17.9m | 17.9m |
Current Assets | 238.8m | 303.1m | 274.0m | 421.5m | 384.9m | 367.1m | 446.8m | 386.7m | 332.6m |
Annual
| USD | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
Net Income | (190.7m) | (285.4m) | (215.5m) |
Depreciation and Amortization | 3.1m | 4.0m | 3.2m |
Inventories | (3.2m) | (7.3m) | (1.6m) |
Accounts Payable | (16.4m) | 3.8m | 3.6m |
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (42.1m) | (89.4m) | (123.3m) | (65.3m) | (131.6m) | (198.5m) | (65.1m) | (105.9m) | (165.3m) |
Depreciation and Amortization | 699.0k | 1.2m | 1.9m | 1.1m | 2.1m | 3.0m | 900.0k | 1.7m | 2.3m |
Inventories | 134.0k | 157.0k | (1.8m) | 140.0k | (497.0k) | (3.0m) | (371.0k) | (351.0k) | (552.0k) |
Accounts Payable | (9.4m) | (10.8m) | (12.8m) | 2.0m | 4.8m | 3.5m | (449.0k) | (2.3m) | (1.7m) |
| USD | Y, 2018 |
|---|---|
EV/EBIT | -4.9 x |
EV/CFO | -10.4 x |
Debt/Equity | -4.4 x |
Debt/Assets | 0.4 x |
Financial Leverage | -10.9 x |
Theravance Biopharma Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Theravance Biopharma Antibiotics IP | ||
| Theravance Biopharma Ireland Limited | ||
| Theravance Biopharma R&D | ||
| Theravance Biopharma R&D IP | ||
| Theravance Biopharma UK Limited | ||
| Theravance Biopharma US | ||
| Triple Royalty Sub LLC |
Theravance Biopharma Revenue Breakdown
Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other
Theravance Biopharma Online and Social Media Presence
Theravance Biopharma's Trends
Theravance Biopharma Company Culture
Overall Culture
B-
75/100
CEO Rating
A
80/100
Compensation
D
54/100
Theravance Biopharma News and Updates
February 12, 2020
Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares
DUBLIN, Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the...
December 03, 2019
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
DUBLIN, Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK)...
September 09, 2019
Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial...
June 14, 2019
Theravance Biopharma and Mylan Expand YUPELRI (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories.read more
May 21, 2019
Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019
DUBLIN, Ireland, May 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported data from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473, in an oral presentation at Digestive...
May 20, 2019
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety...
Theravance Biopharma Blogs
March 02, 2020
Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes
Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes
Content Import
Mon, 03/02/2020 - 07:01
Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes
March 2, 2020 at 7:00 AM EST
Th…
February 24, 2020
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Content Import
Mon, 02/24/2020 - 16:06
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Febr…
February 18, 2020
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
Content Import
Tue, 02/18/2020 - 07:01
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
February 18, 2020 at 7:00 AM EST
This release is a backfill from …
February 13, 2020
Theravance Biopharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
DUBLIN , Feb. 13, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2019 financial and operating
February 10, 2020
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares
Content Import
Mon, 02/10/2020 - 16:01
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares
February 10, 2020 at 4:01 PM EST
This release is a backfill from a News…
January 07, 2020
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Content Import
Tue, 01/07/2020 - 16:49
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
January 7, 2020 at 4:48 PM EST
…
Theravance Biopharma Frequently Asked Questions
When was Theravance Biopharma founded?
Theravance Biopharma was founded in 1996.
Who are Theravance Biopharma key executives?
Theravance Biopharma's key executives are Rick Winningham, Eran Broshy and Dennis O. Driver.
How many employees does Theravance Biopharma have?
Theravance Biopharma has 363 employees.
What is Theravance Biopharma revenue?
Latest Theravance Biopharma annual revenue is $60.4 m.
What is Theravance Biopharma revenue per employee?
Latest Theravance Biopharma revenue per employee is $166.3 k.
Who are Theravance Biopharma competitors?
Competitors of Theravance Biopharma include Prothena, Inflazome and Aimmune Therapeutics.
Where is Theravance Biopharma headquarters?
Theravance Biopharma headquarters is located at Connaught House, 1 Burlington Rd, Dublin.
Where are Theravance Biopharma offices?
Theravance Biopharma has offices in Dublin and San Francisco.
How many offices does Theravance Biopharma have?
Theravance Biopharma has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies